2μg (R: reducing condition, N:non-reducing condition).
Povetacicept
Povetacicept
Price:
Regular price
$240 USD
Regular price
Sale price
$240 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Synonyms | Povetacicept, ALPN-303 |
| Expression System | HEK293 |
| Molecular Weight | 55-60kDa (Non-Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Conjugation | Unconjugated |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1.Stacey Dillon, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front. Immunol., 06 June 2025. |
Background
Povetacicept (ALPN-303) is an engineered Fc fusion protein consisting of a variant domain of human TACI receptor (containing key amino acid substitutions) fused to an effector-less human IgG1 Fc fragment, functioning as a dimer to exert high-affinity dual antagonistic activity. Its mechanism of action is achieved through simultaneous binding and inhibition of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL)—the former regulates early B-cell development and activates T cells, while the latter supports plasma cell survival, both collectively driving pathogenic B-cell and autoantibody production. Clinical studies (RUBY-3) have demonstrated that this agent reduces proteinuria by 64% and galactose-deficient IgA1 by 77% in IgA nephropathy, with approximately 90% of patients achieving resolution of hematuria; in membranous nephropathy, anti-PLA2R antibodies decreased by 83%, with 100% reaching immunological remission, and the safety profile has been favorable. Currently, a Phase III confirmatory study (RAINIER) has been initiated in IgA nephropathy, and the drug has also shown therapeutic potential in other autoantibody-associated diseases such as myasthenia gravis.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of Povetacicept is more than 95% as determined by SEC-HPLC.
SPR
Protein A Chip captured Povetacicept (Cat. No. UA016160), can bind BAFF/TNFSF13B/CD257 Trimer His Tag Protein, Human (Cat. No. UA016073) with an affinity constant of 82.34pM as determined in SPR assay.
Protein A Chip captured Povetacicept (Cat. No. UA016160), can bind BAFF&APRIL Heterotrimer His Tag Protein, Human (Cat. No. UA011338) with an affinity constant of 0.12nM as determined in SPR assay.
